27.07.2011 • News

Biogen Idec Posts Q2 Profit Of $288 Million

Biogen Idec posted second-quarter net income attributable to the company of $288.03 million or $1.18 per share compared to $293.44 million or $1.12 per share last year.

Non-GAAP net income attributable to the company was $332.2 million or $1.36 per share versus $343.2 million or $1.31 per share a year ago.
Quarterly revenues stood flat at $1.21 billion.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.37 per share on revenues of $1.18 billion for the quarter. Analysts' estimates typically exclude special items.

Going ahead, the company revised outlook for 2011. The company now expects earnings per share to be above $4.91. Non-GAAP earnings per share is expected to be above $5.70. Analysts expect earnings of $5.85 per share for the year.

Also, for 2011, revenue growth is expected to be in the low to mid-single digits versus 2010. Analysts anticipate revenues of $4.83 billion for the year.

 

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read